share_log

诺泰生物获东海证券买入评级,业绩显著超预期

JRJ Finance ·  Aug 27, 2024 16:07  · Ratings

8月27日,诺泰生物获东海证券买入评级,近一个月诺泰生物获得8份研报关注。

研报预计2024-2026年归母净利润分别为4.12/5.61/7.16亿。研报认为,公司中报业绩显著超预期,受益于GLP-1等多肽行业的快速发展,公司竞争优势持续扩大,预计公司业绩仍将保持快速增长态势。

风险提示:市场竞争风险、汇率波动风险、研发风险、集采降价超预期风险等。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment